Drug Profile
Fosdenopterin - Origin Biosciences
Alternative Names: ALXN-1101; BBP-870; cPMP; cPMP-cpd; Cyclic pyranopterin monophosphate (cPMP) replacement therapy - Origin Biosciences; Cyclic pyranopterin monophosphate - Origin Biosciences; Nulibry; ORGN 001Latest Information Update: 06 Nov 2022
Price :
$50
*
At a glance
- Originator Orphatec Pharmaceuticals
- Developer BridgeBio Pharma; Origin Biosciences; Sentynl Therapeutics
- Class Alkadienes; Amines; Aza compounds; Ketones; Organophosphorus compounds; Pterins; Pyrans; Small molecules
- Mechanism of Action Molybdenum cofactor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Molybdenum cofactor deficiency
Most Recent Events
- 17 Oct 2022 Origin Biosciences completes a phase II/III trial in in Molybdenum cofactor deficiency (In children, In infants, In neonates) in the US, Israel, Norway, Spain, Turkey and the United Kingdom (NCT02629393) (EudraCT2013-002702-30)
- 17 Oct 2022 Origin Biosciences completes a phase II trial in Molybdenum cofactor deficiency (In children, In infants, In neonates) in the US, the UK, Australia, Tunisia and the Netherlands (IV) (NCT02047461)
- 21 Sep 2022 Registered for Molybdenum cofactor deficiency (In children, In infants, In neonates) in Liechtenstein, Iceland, Norway, European Union (IV)